Valuation: Insmed Incorporated

Market Cap 22.35B 19.64B 18.33B 16.82B 31.49B 2,141B 32.27B 217B 85.02B 1,059B 83.92B 82.1B 3,662B P/E 2026 *
-40.4x
P/E 2027 * 204x
Enterprise Value 21.79B 19.15B 17.87B 16.4B 30.7B 2,087B 31.46B 212B 82.87B 1,033B 81.8B 80.03B 3,570B EV / Sales 2026 *
12.8x
EV / Sales 2027 * 7.7x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day-1.77%
1 week-3.30%
Current month-3.28%
1 month-1.55%
3 months-23.63%
6 months-34.66%
Current year-40.75%
1 week 102.81
Extreme 102.81
108.27
1 month 102.81
Extreme 102.81
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.94
Extreme 20.94
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
-1.73%-3.30%-1.79%+383.00% 22.35B
-3.12%-5.47%+44.00%+64.86% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
-0.25%+1.22%-16.62%-13.47% 23.51B
-4.01%-3.67%+13.17%-14.29% 20.6B
-2.08%-3.62%+25.38%-34.16% 17.45B
-3.34%-7.77%+23.78%+536.66% 15.16B
-0.71%+0.64%+49.78%+178.74% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
-13.17%+1.72%+85.76%+166.11% 12.61B
Average -2.75%-1.29%+41.70%+164.22% 25.01B
Weighted average by Cap. -1.67%-0.56%+34.72%+128.97%

Financials

2026 *2027 *
Net sales 1.7B 1.49B 1.4B 1.28B 2.4B 163B 2.46B 16.54B 6.47B 80.62B 6.39B 6.25B 279B 2.78B 2.44B 2.28B 2.09B 3.91B 266B 4.01B 27B 10.56B 132B 10.42B 10.2B 455B
Net income -561M -493M -460M -423M -791M -53.76B -810M -5.46B -2.13B -26.6B -2.11B -2.06B -91.97B 71.64M 62.95M 58.76M 53.92M 101M 6.86B 103M 697M 272M 3.4B 269M 263M 11.74B
Net Debt -563M -495M -462M -424M -793M -53.93B -813M -5.48B -2.14B -26.69B -2.11B -2.07B -92.26B -979M -860M -803M -737M -1.38B -93.73B -1.41B -9.52B -3.72B -46.38B -3.67B -3.59B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-29 US$103.12 -0.97% 2,195,533
26-07-28 US$104.13 -0.57% 1,945,719
26-07-27 US$104.73 -2.05% 1,899,713
26-07-24 US$106.92 -0.46% 1,908,298
26-07-23 US$107.41 +0.72% 1,752,962
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
103.12USD
Average target price
196.18USD
Spread / Average Target
+90.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock